Nils Krüger
Dr. Nils Krüger is a prominent researcher affiliated with Brigham and Women’s Hospital and a founding member of the Mass General Brigham healthcare system. He specializes in cardiology and has made significant contributions to understanding heart failure, particularly in patients with obesity and type 2 diabetes. His recent study, presented at the European Society of Cardiology annual conference, highlighted the potential of GLP-1 agonists, such as semaglutide and tirzepatide, to dramatically reduce hospitalizations and early death risks among heart failure patients.
Not in the pool (under ¢1).
Recent news mentions
Nils Krüger, a researcher at Harvard Medical School, stated that even if a person stops losing weight while taking these drugs, the medication can still provide cardiovascular benefits.
La realidad detrás de los medicamentos para perder peso
Honduras· 2026-02-08
Dr Nils Krüger, of Brigham and Women’s hospital, is a study author who discussed the benefits of GLP-1 targeting medications for heart failure patients.
Weight loss drugs can halve heart patients’ risk of early death, study finds | Health
United Kingdom· 2025-08-31
